MCNS
MCID: LPD004
MIFTS: 46

Lipoid Nephrosis (MCNS)

Categories: Blood diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lipoid Nephrosis

MalaCards integrated aliases for Lipoid Nephrosis:

Name: Lipoid Nephrosis 11 14 16 71 75
Minimal Change Disease 11 19 5 75
Nephrotic Syndrome with Lesion of Minimal Change Glomerulonephritis 11
Nephrotic Syndrome with Lesion of Minimal Change Nephrotic Syndrome 11
Idiopathic Minimal Change Nephrotic Syndrome 19
Glomerulonephritis, Minimal Change 71
Nephrotic Syndrome, Minimal Change 71
Minimal Change Glomerulonephritis 11
Minimal Change Nephrotic Syndrome 19
Nephrotic Syndrome Minimal Change 53
Minimal Change Glomerulopathy 19
Nephrosis, Lipoid 43
Mcns 19

Classifications:



External Ids:

Disease Ontology 11 DOID:10966
MeSH 43 D009402
NCIt 49 C34844
SNOMED-CT 68 197592009
ICD10 31 N04
UMLS 71 C0027721 C1704320 C1704321

Summaries for Lipoid Nephrosis

GARD: 19 Minimal change disease is a kidney disease in which there is damage to the filtering units of the kidney (glomeruli). It is the most common cause of nephrotic syndrome in children. Nephrotic syndrome is comprised of a group of symptoms including protein in the urine (proteinuria), low protein levels in the blood, high cholesterol and triglycerides, an increased risk for blood clots, and swelling. Other symptoms of this disease include weight gain and a foamy appearance of the urine. The cause of Minimal change disease is unknown, but it may occur following an allergic reaction or infection.

MalaCards based summary: Lipoid Nephrosis, also known as minimal change disease, is related to nephrotic syndrome, type 23 and idiopathic nephrotic syndrome. An important gene associated with Lipoid Nephrosis is LMX1B (LIM Homeobox Transcription Factor 1 Beta), and among its related pathways/superpathways are Cell junction organization and NF-kappaB Signaling. The drugs Mycophenolic acid and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, pancreas and t cells, and related phenotypes are nervous system and renal/urinary system

Wikipedia: 75 Minimal change disease (also known as MCD, minimal change glomerulopathy, and nil disease, among others)... more...

Related Diseases for Lipoid Nephrosis

Diseases related to Lipoid Nephrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 534)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome, type 23 32.2 SYNPO NPHS2
2 idiopathic nephrotic syndrome 31.1 NPHS2 NPHS1
3 end stage renal disease 30.9 LMX1B CD2AP APOL1 ACTN4
4 acute kidney tubular necrosis 30.8 NAGLU CCL2 APOL1 ALB
5 proliferative glomerulonephritis 30.8 PLA2R1 CD79A CCL2 ALB
6 strongyloidiasis 30.8 IL13 IL10 CD79A
7 tetanus 30.7 IL13 IL10 CD79A ALB
8 nephrotic syndrome, type 2 30.7 NPHS2 NPHS1
9 nephrotic syndrome, type 10 30.7 PODXL NPHS2 NPHS1
10 microvascular complications of diabetes 3 30.6 SERPINB7 NPHS1 NAGLU ALB
11 pulmonary tuberculosis 30.6 IL10 CCL2 ALB
12 nephrotic syndrome, type 1 30.5 NPHS2 NPHS1 CD2AP ACTN4
13 interstitial nephritis 30.5 PLA2R1 APOL1 ALB
14 nephrotic syndrome, type 4 30.5 NPHS2 NPHS1
15 igg4-related disease 30.5 PLA2R1 IL13 IL10
16 peritonitis 30.5 IL10 CCL2 ALB
17 hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome 30.5 NPHS2 NPHS1 ACTN4
18 rapidly progressive glomerulonephritis 30.5 PLA2R1 NPHS1 ALB
19 hematuria, benign familial 30.4 NPHS2 NPHS1 CD2AP ACTN4
20 membranoproliferative glomerulonephritis 30.4 SYNPO PLA2R1 NPHS2 NPHS1 CD79A APOL1
21 nephrosclerosis 30.4 SYNPO NPHS2 NPHS1 CCL2
22 vesicoureteral reflux 30.4 NPHS2 NAGLU LMX1B ALB
23 glomerulonephritis 30.4 SYNPO PLA2R1 NPHS2 NPHS1 IL10 CD79A
24 sarcoidosis 1 30.3 IL13 IL10 CCL2 ALB
25 goodpasture syndrome 30.3 PLA2R1 NPHS1 ALB
26 fabry disease 30.3 SYNPO LMX1B IL10
27 behcet syndrome 30.3 IL13 IL10 CCL2 ALB
28 otitis media 30.3 IL13 IL10 CD79A CCL2 ALB
29 iga glomerulonephritis 30.3 SERPINB7 PLA2R1 NPHS2 NPHS1 CD79A CD2AP
30 mesangial proliferative glomerulonephritis 30.2 SYNPO PLA2R1 NPHS2 NPHS1 CD79A CCL2
31 meningoencephalitis 30.2 IL10 CD79A ALB
32 anti-basement membrane glomerulonephritis 30.2 PLA2R1 ALB
33 membranous nephropathy 30.1 SYNPO SERPINB7 PLA2R1 NPHS2 NPHS1 CD79A
34 respiratory failure 30.1 IL13 IL10 CCL2 ALB
35 renal hypertension 30.1 NPHS2 NPHS1 APOL1 ALB
36 focal segmental glomerulosclerosis 2 30.1 NPHS2 NPHS1 CD2AP ACTN4
37 polycystic kidney disease 30.1 PODXL NPHS2 NPHS1 CCL2 ALB
38 focal segmental glomerulosclerosis 1 30.1 SYNPO NPHS2 NPHS1 ACTN4
39 hydronephrosis 30.1 NAGLU CCL2 ALB
40 primary biliary cholangitis 30.0 IL10 CD79A CCL2 ALB
41 skin disease 30.0 ITGB1 IL13 IL10 CD79A CCL2 ALB
42 autosomal dominant polycystic kidney disease 30.0 PODXL NPHS2 NPHS1 CCL2 APOL1 ALB
43 hypertension, essential 29.9 NPHS2 NPHS1 IL13 IL10 CCL2 APOL1
44 chronic kidney disease 29.8 TF SERPINB7 NPHS2 NPHS1 CD79A ALB
45 familial nephrotic syndrome 29.8 SYNPO PODXL NPHS2 NPHS1 LMX1B CD2AP
46 nephrotic syndrome 29.7 TF SYNPO SMPDL3B PODXL NPHS2 NPHS1
47 alport syndrome 29.7 SYNPO PODXL NPHS2 NPHS1 LMX1B CD79A
48 wilms tumor 1 29.6 SYNPO PODXL NPHS2 NPHS1 CD2AP ALB
49 kidney disease 29.4 TF SERPINB7 NPHS2 NPHS1 NAGLU LMX1B
50 focal segmental glomerulosclerosis 29.1 SYNPO SMPDL3B PODXL NPHS2 NPHS1 MIR1915

Graphical network of the top 20 diseases related to Lipoid Nephrosis:



Diseases related to Lipoid Nephrosis

Symptoms & Phenotypes for Lipoid Nephrosis

MGI Mouse Phenotypes related to Lipoid Nephrosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 ACTN4 CCL2 CD79A IL10 IL13 ITGB1
2 renal/urinary system MP:0005367 10 ACTN4 ALB CD2AP CD79A ITGB1 LMX1B
3 homeostasis/metabolism MP:0005376 10 ACTN4 ALB CCL2 CD2AP CD79A IL10
4 neoplasm MP:0002006 9.91 ACTN4 ALB CCL2 CD79A IL10 ITGB1
5 cardiovascular system MP:0005385 9.73 ACTN4 ALB APOL1 CCL2 CD2AP IL10
6 mortality/aging MP:0010768 9.47 ACTN4 ALB CCL2 CD2AP CD79A IL10

Drugs & Therapeutics for Lipoid Nephrosis

Drugs for Lipoid Nephrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
9
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
10
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
12 Vaccines Phase 4
13 Cyclosporins Phase 4
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
15 Calcineurin Inhibitors Phase 4
16 Immunologic Factors Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Antitubercular Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22 Hormones Phase 4
23 Hormone Antagonists Phase 4
24 glucocorticoids Phase 4
25 Anti-Inflammatory Agents Phase 4
26
Methylprednisolone Acetate Phase 4 584547
27 Vitamins Phase 4
28 Trace Elements Phase 4
29 Calciferol Phase 4
30 Hydroxycholecalciferols Phase 4
31 Micronutrients Phase 4
32
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
33
Rituximab Approved Phase 2, Phase 3 174722-31-7
34
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
35
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
36 Neurotransmitter Agents Phase 2, Phase 3
37 Psychotropic Drugs Phase 2, Phase 3
38 Anticonvulsants Phase 2, Phase 3
39 Immunoglobulins Phase 3
40 Antibodies Phase 3
41 Antirheumatic Agents Phase 3
42 Antineoplastic Agents, Immunological Phase 2, Phase 3
43 Immunosuppressive Agents Phase 3
44 Histamine Antagonists Phase 3
45 Alkylating Agents Phase 3
46 Antineoplastic Agents, Alkylating Phase 3
47
Abatacept Approved Phase 2 332348-12-6
48
Adalimumab Approved, Experimental Phase 2 331731-18-1
49 Immune Checkpoint Inhibitors Phase 2
50 Immunoglobulins, Intravenous Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome Unknown status NCT02649413 Phase 4 Prednisone
2 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
3 Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease Completed NCT00982072 Phase 4 tacrolimus;prednisolone
4 Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
5 Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome Completed NCT01185197 Phase 4 Myfortic plus low-dose steroid;Prednisolone
6 Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
7 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone Unknown status NCT03298698 Phase 3 Rituximab;Prednisone
8 A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome Unknown status NCT02896270 Phase 2, Phase 3 Valproic Acid
9 A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
10 A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study) Completed NCT00981838 Phase 3 Rituximab
11 Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
12 Cyclophosphamide Versus Mycophenolate Mofetil for Children With Steroid-dependent Idiopathic Nephrotic Syndrome : a Multicenter Randomized Controlled Trial Completed NCT01092962 Phase 3 Cyclophosphamide;Mycophenolate mofetil
13 A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
14 Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome Completed NCT04494438 Phase 3 Rituximab
15 A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) Completed NCT02592798 Phase 2 Abatacept
16 Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Recruiting NCT04009668 Phase 2 adalimumab
17 A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases Recruiting NCT05003986 Phase 2 Sparsentan
18 A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS) Recruiting NCT05441826 Phase 2 VB119
19 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Recruiting NCT03970577 Phase 2 Rituximab;Prednisone
20 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Terminated NCT04387448 Phase 2 GFB-887;Placebo
21 A Study on the Diagnosis of Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and Gastroesophageal Reflux Disease Using Linked Color Imaging Unknown status NCT03068572
22 The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project Unknown status NCT03786263
23 Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease Completed NCT04369183
24 The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy Completed NCT01451710 Prednisone or Prednisolone
25 Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics Completed NCT02869893 Secretin
26 Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome Completed NCT00577525
27 Effect of Daily Transcutaneous Auricular Vagus Nerve (taVNS) Stimulation on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome Completed NCT04169776
28 Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome Completed NCT01609426
29 A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Steroid Resistant Nephrotic Syndrome in Children Recruiting NCT05583942
30 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
31 A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children Recruiting NCT05588063
32 The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) Recruiting NCT03949972
33 Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network Recruiting NCT01209000
34 Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome Recruiting NCT05505500
35 A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood. Recruiting NCT04207580
36 Nephrotic Syndrome Study Network (NEPTUNE) Match Study Enrolling by invitation NCT04571658
37 A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) Terminated NCT04235621

Search NIH Clinical Center for Lipoid Nephrosis

Cochrane evidence based reviews: nephrosis, lipoid

Genetic Tests for Lipoid Nephrosis

Anatomical Context for Lipoid Nephrosis

Organs/tissues related to Lipoid Nephrosis:

MalaCards : Kidney, Pancreas, T Cells, Endothelial, Lymph Node, Monocytes, Smooth Muscle

Publications for Lipoid Nephrosis

Articles related to Lipoid Nephrosis:

(show top 50) (show all 3930)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
Genetic effect of the NPHS2 gene variants on proteinuria in minimal change disease and immunoglobulin A nephropathy. 53 62
20025681 2009
3
Historical development of the renal histopathology services in Malaysia. 53 62
19694308 2009
4
A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. 53 62
18985619 2009
5
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 53 62
19562271 2009
6
Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. 53 62
18032547 2008
7
Expression profile of nephrin, podocin, and CD2AP in Chinese children with MCNS and IgA nephropathy. 53 62
16941146 2006
8
Role of podocyte slit diaphragm as a filtration barrier. 53 62
16889564 2006
9
Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome. 53 62
16739878 2006
10
Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. 53 62
16759810 2006
11
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 53 62
16285662 2005
12
Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome. 53 62
15687724 2005
13
Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). 53 62
15086927 2004
14
[Pathogenesis of immune glomerulonephritis]. 53 62
15008213 2003
15
Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry. 53 62
12830459 2003
16
Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. 53 62
12787429 2003
17
Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. 53 62
12480962 2003
18
Quantitative analyses of osteopontin mRNA expression in human proximal tubules isolated from renal biopsy tissue sections of minimal change nephrotic syndrome and IgA glomerulonephropathy patients. 53 62
11979338 2002
19
Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up-regulation in IgA nephropathy. 53 62
11527413 2001
20
Does albumin and furosemide therapy affect plasma volume in nephrotic children? 53 62
11420914 2001
21
Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. 53 62
11157380 2001
22
Adrenomedullin and nitrite levels in children with minimal change nephrotic syndrome. 53 62
11095016 2000
23
Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. 53 62
10589701 1999
24
Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. 53 62
10412778 1999
25
Influence of serum albumin on renal function in nephrotic syndrome. 53 62
10100284 1999
26
Diagnostic value of urinary retinol-binding protein in childhood nephrotic syndrome. 53 62
9811386 1998
27
Tubulointerstitial mast cell infiltration in glomerulonephritis. 53 62
9774120 1998
28
Plasma and urinary levels of adrenomedullin in chronic glomerulonephritis patients with proteinuria. 53 62
9736825 1998
29
Expression of beta 1-integrins on activated mesangial cells in human glomerulonephritis. 53 62
9355070 1997
30
Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. 53 62
9346389 1997
31
Serum tumor necrosis factor in mesangial IgA glomerulonephritis with macroscopic hematuria in children. 53 62
8730414 1996
32
[The effect of peripheral blood mononuclear cell products from children with nephrotic syndrome on thromboxane A2 metabolism]. 53 62
7619008 1995
33
Sodium dodecyl sulphate polyacrylamide gel electrophoresis of urinary proteins in steroid-responsive and steroid-resistant nephrotic syndrome in children. 53 62
7696097 1994
34
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. 53 62
8196081 1994
35
An immunohistochemical study of extracellular matrix components and integrins in human glomerular diseases. 53 62
8022108 1994
36
The differential diagnostic value of urinary enzyme and amino acid excretion in children with nephrotic syndrome. 53 62
7912541 1994
37
Histone-reactive IgA antibodies in adult IgA nephropathy and other primary glomerulonephritis. 53 62
7527503 1994
38
Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group. 53 62
7620220 1994
39
Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. 53 62
8247178 1993
40
Studies on the role of interleukin-4 and Fc epsilon RII in the pathogenesis of minimal change nephrotic syndrome. 53 62
1299237 1992
41
Lymphocyte release of soluble IL-2 receptors in patients with minimal change nephropathy. 53 62
1582055 1992
42
Aggravation of minimal change nephrotic syndrome by administration of human albumin. 53 62
1563113 1992
43
[Studies on Hanganutziu-Deicher antibodies in renal diseases]. 53 62
1316976 1992
44
Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. 53 62
1682080 1991
45
Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. 53 62
1709070 1991
46
An analysis of 2361 cases of renal biopsy in Korea. 53 62
1877261 1991
47
[Minimal change nephrotic syndrome with predominant mesangial IgA deposits: clinicopathological study]. 53 62
2051642 1991
48
Mesangial immunoglobulin A deposits in minimal change nephrotic syndrome: a report of an older patient and review of the literature. 53 62
2111636 1990
49
The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. 62
35659570 2022
50
The spectrum and changes of biopsy-proven kidney diseases in Chinese children. 62
36472788 2022

Variations for Lipoid Nephrosis

ClinVar genetic disease variations for Lipoid Nephrosis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LMX1B NM_001174147.2(LMX1B):c.737G>C (p.Arg246Pro) SNV Likely Pathogenic
812901 rs1191455921 GRCh37: 9:129455598-129455598
GRCh38: 9:126693319-126693319

Expression for Lipoid Nephrosis

Search GEO for disease gene expression data for Lipoid Nephrosis.

Pathways for Lipoid Nephrosis

GO Terms for Lipoid Nephrosis

Cellular components related to Lipoid Nephrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.96 TF SMPDL3B SERPINB7 PODXL IL13 IL10
2 slit diaphragm GO:0036057 9.1 PODXL NPHS2 NPHS1

Sources for Lipoid Nephrosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....